CAMBRIDGE, Mass.--(BUSINESS WIRE)--PROMETRIKA (www.prometrika.com), a boutique full service clinical research organization, is coordinating a Phase 1 trial for The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science. PROMETRIKA is responsible for the clinical trial management and site monitoring, medical monitoring, database implementation and data management, study drug management, pharmacovigilance, biostatistics, and medical writing. This trial is in acute myeloid leukemia (AML), which is a rare form of cancer with approximately 10,500 new cases each year in the United States.
“We are thrilled to work on this important trial alongside the institution in its pursuit to end cancer,” said Miganush Stepanians, Ph.D., President and CEO of PROMETRIKA.
As a CRO focused on both rare diseases and oncology, this study presents another opportunity for PROMETRIKA to leverage its considerable expertise and experience in AML in the ongoing fight against this devastating disease.
About PROMETRIKA, LLC - www.prometrika.com
Founded in 2003 and based in Cambridge, Massachusetts, PROMETRIKA is a unique Clinical Research Organization (CRO), utilizing a collaborative approach to clinical development and execution with a close-knit, highly-experienced senior leadership team involved in all phases of trials. PROMETRIKA’s services include complete clinical operations and clinical trial management, data management, pharmacovigilance, biostatistics and programming, medical writing, and regulatory submissions.